HCRTR2 and insomnia: To date, the OX2R agonist TAK-861 has shown no hepatotoxicity in trials, with adverse events primarily mild to moderate (e.g., controllable insomnia, urinary urgency, and frequency), suggesting strong potential for clinical application.